Department of Respiratory Diseases and Allergology, Aarhus University Hospital, Aarhus, Denmark.
Respirology. 2012 Aug;17(6):927-32. doi: 10.1111/j.1440-1843.2012.02189.x.
Bronchiectasis is a chronic disorder characterized by impaired mucociliary clearance and a relentless cycle of infection, inflammation and bronchial wall injury, which has a debilitating impact on the patient's quality of life and results in increased morbidity and mortality. It is a disease for which there are no currently registered therapeutic products, limited epidemiological data and no validated endpoints that have been accepted by the majority of regulatory authorities. This article reviews the evidence base for the efficacy of inhaled dry powder mannitol in patients with non-cystic fibrosis (CF) bronchiectasis. The few published papers on this topic concluded that mannitol, when inhaled as a dry powder, is a promising treatment for bronchiectasis. It is designed to hydrate the lungs and restore normal mucociliary clearance mechanisms in the lungs. Based on the available evidence, mannitol inhalation is well tolerated and improves the quality of life of patients with non-CF bronchiectasis. There is a need for well designed and adequately powered multicentre trials to establish the potential usefulness of mannitol as a treatment for non-CF bronchiectasis.
支气管扩张症是一种慢性疾病，其特征为黏液纤毛清除功能受损以及持续的感染、炎症和支气管壁损伤循环，这对患者的生活质量造成了严重影响，并导致发病率和死亡率上升。目前尚无针对该疾病的注册治疗产品，其流行病学数据有限，也没有被大多数监管机构认可的验证终点。本文回顾了吸入性干粉甘露醇治疗非囊性纤维化（CF）支气管扩张症患者的疗效证据。关于该主题的少数已发表的论文得出结论，甘露醇作为干粉吸入剂，是治疗支气管扩张症的一种很有前途的方法。它旨在使肺部保持水分并恢复肺部正常的黏液纤毛清除机制。基于现有证据，甘露醇吸入具有良好的耐受性，并可改善非 CF 支气管扩张症患者的生活质量。需要精心设计和充分有力的多中心试验来确定甘露醇作为非 CF 支气管扩张症治疗方法的潜在用途。
